<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928144</url>
  </required_header>
  <id_info>
    <org_study_id>SHJ002-CS201</org_study_id>
    <nct_id>NCT04928144</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects</brief_title>
  <official_title>An Intra-subject Dose Escalation Phase 1 Study to Determine the Safety and Tolerability of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunhawk Vision Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunhawk Vision Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, first-in-human dose-escalation study of SHJ002&#xD;
      Ophthalmic Solution in children. (Part 1) Three (3) subjects will receive each concentration&#xD;
      of SHJ002 for 3 days in an escalation design in one eye. (Part 2) A Group of 9 additional&#xD;
      children will receive the highest tolerated concentration for 28 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single-center, Open-label, first-in-human dose-escalation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in best corrected visual acuity</measure>
    <time_frame>3 days (Part 1) and 28 days (Part 2)</time_frame>
    <description>Change from baseline in best corrected visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>3 days (Part 1) and 28 days (Part 2)</time_frame>
    <description>Incidence of Adverse Events</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>0.025% SHJ002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.025% SHJ002 Sterile Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.080% SHJ002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.080% SHJ002 Sterile Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25% SHJ002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25% SHJ002 Sterile Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHJ002 - Maximum tolerated concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum tolerated concentration of SHJ002</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHJ - Low concentration</intervention_name>
    <description>Topical ophthalmic</description>
    <arm_group_label>0.025% SHJ002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHJ - Mid concentration</intervention_name>
    <description>Topical ophthalmic</description>
    <arm_group_label>0.080% SHJ002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHJ - High concentration</intervention_name>
    <description>Topical ophthalmic</description>
    <arm_group_label>0.25% SHJ002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHJ - Maximum tolerated</intervention_name>
    <description>SHJ - Maximum tolerated</description>
    <arm_group_label>SHJ002 - Maximum tolerated concentration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-cycloplegic sphere from +1.50 to -4.75 Diopters in one or both eyes.&#xD;
&#xD;
          -  A minor able to complete all study assessments and comply with the protocol and has a&#xD;
             parent or caregiver willing and able to follow study instructions, comply with the&#xD;
             protocol and attend study visits with the subject as required, in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          -  Literate and able to orally communicate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-cycloplegic sphere worse than -4.75 Diopters&#xD;
&#xD;
          -  Axial length &gt; 26 mm&#xD;
&#xD;
          -  Hyperopia worse than +1.50 Diopters&#xD;
&#xD;
          -  Anisometropia (difference of myopic power &gt;2.00 D).&#xD;
&#xD;
          -  Astigmatism &gt; 1.5 D.&#xD;
&#xD;
          -  Intraocular pressure &gt; 21 mm Hg or &lt; 6 mm Hg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suh-Hang H. Juo, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sunhawk Vision Biotech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

